Application value of radiotherapy combined with immunotherapy in elderly patients with advanced non-small cell lung cancer
CSTR:
Author:
Affiliation:

(1.Department of Oncology, West China Hospital, Sichuan University, Chengdu 610000, China;2.Department of Oncology, First People′s Hospital of Liangshan Yi Autonomous Prefecture, Xichang 615000, Sichuan Province, China)

Clc Number:

Fund Project:

This work was supported byNatural Science Foundation of Sichuan Province(2022NSFSC1465).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective To analyze the application value of radiotherapy combined with immunotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 206 elderly patients with advanced NSCLC admitted to the First People′s Hospital of Liangshan Yi Autonomous Prefecture from January 2018 to August 2023 were selected as the study subjects. According to the treatment regimens, the patients were divided into an immunotherapy group (n=101) treated with programmed cell death receptor 1 (PD-1) immune checkpoint inhibitors and a combination therapy group (n=105) treated with PD-1 inhibitors combined with volume rotation intensity modulated radiation therapy (VMAT). The two groups were compare in the clinical efficacy, T-cell subsets (CD4+, CD8+, CD4+/CD8+), pulmonary function [forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC] before and after treatment, and adverse reactions. SPSS 25.0 was used for data processing. Kaplan-Meier survival curves were used to analyze the difference in progression-free survival (PFS) at 15 months after the beginning of treatment in the two groups. Results The objective response rate (50.48% vs 35.64%) and disease control rate (81.90% vs 69.31%) in the combination therapy group were higher than those in the immunotherapy group (P<0.05). After the treatment, CD4+, CD4+/CD8+, FEV1, FVC and FEV1/FVC in both groups increased as compared with before treatment (P<0.05), and the above indicators in the combination therapy group after treatment were higher than those in the immunotherapy group (P<0.05). With 15 months of treatment as the end point, the disease progression rate was 30.48% (32/105) in the combination therapy group and 48.51% (49/101) in the immunotherapy group. Kaplan-Meier curve analysis showed that the median PFS of the combination therapy group [12.41 months (95%CI 11.564-13.255)] was significantly longer than that of the immunotherapy group [10.56 months (95%CI 9.576-11.553)], and the difference was statistically significant (Log-rank χ2=7.465, P=0.006). Conclusion VMAT combined with PD-1 inhibitor immunotherapy not only helps enhance the clinical efficacy in elderly patients with advanced NSCLC with good safety but also has positive significance in improving immunity function and pulmonary function and increasing PFS.

    Reference
    Related
    Cited by
Get Citation
Related Videos

Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:January 18,2025
  • Revised:
  • Adopted:
  • Online: February 03,2026
  • Published:
Article QR Code